Wisconsin’s consistently strong rankings for quality health care are a tangible marketing asset in the competition to attract and retain workers and businesses from other states, regions and nations. Those are among conclusions in “Taking the Pulse: How Quality Health Care Builds a Better Economy,”...
The University of Wisconsin–Madison will host three on-campus events in February to gather feedback about the current layout of the west side of campus and future improvements planned for the West Campus District....
Emerging companies may apply through Feb. 22 to meet with major firms and explore potential business relationships around technology needs and innovation as part of the 10th annual Wisconsin Tech Summit, which will take place in-person at Green Bay’s Lambeau Field. The day-long event will...
Nimble Therapeutics is expanding its collaboration with Genentech, a member of the Roche Group, for the discovery of peptide therapies for the treatment of diseases across multiple therapeutic areas....
MadREP and the Madison Region enjoyed a number of wins, accomplishments and rankings in 2022. Here’s our ranking of the top ten!...
Nimble Therapeutics Inc., a leading peptide therapeutics company, today announced they have achieved discovery milestones for two programs partnered with a large pharma company. ...
Nimble Therapeutics, an industry-leading peptide therapeutics company, today announced the appointment of Pete Gough, D. Phil. as Chief Scientific Officer (CSO)....
In its fifth year, the Wisconsin Inno Fire Awards honors individuals, companies and organizations across the state that are setting the technology ecosystem ablaze....
About three-quarters of the record $333 billion invested in 2021 wound up in three states – California, New York and Massachusetts. A number of focus for the rest of the United States, however, is where jobs created by venture-backed companies can be found. Nearly two-thirds...
FluGen, based on research by UW-Madison scientists Yoshihiro Kawaoka and Gabriele Neumann, is raising money and exploring relationships with large drug companies to conduct larger studies that could lead to approval of its intranasal vaccine within four years, its leader said....